Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472030 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00472030 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 2 participants.
The verdict
NCT00472030, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study. Patients treated with Xolair will be compared to patients receiving standard treatment with prednisone. The enrollment period for the study is 24 weeks: 16 weeks active treatment and 8 additional weeks of observation.
Interventions
- DRUG prednisone
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472030
The ClinicalTrials.gov registry entry for NCT00472030 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00472030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472030 about?
NCT00472030 is a clinical study titled "Efficacy and Safety of Omalizumab in Bullous Pemphigoid". The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study. Patients treated with Xolair will be compared to patients receiving standard treatment with prednisone. ...
What is the current status of trial NCT00472030?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2007-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00472030?
The interventions under investigation include: prednisone (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00472030?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.